Male Hypogonadism Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The market is segmented By Therapy Type (Testosterone Replacement Therapy, Gonadotropin-Releasing Hormones Therapy), By Application and Geography.

Market Snapshot

Male Hypogonadism Market Overview
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.1 %
Male Hypogonadism Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Male Hypogonadism Market is expected to register a CAGR of 5.1% during the forecast period. Male hypogonadism or testosterone deficiency is a condition in which the body doesn't produce enough of the hormone that plays a key role in development and masculine growth during puberty or enough sperm or both. Hypogonadism may occur at any age, and the consequences differ, according to when it starts. In adult men, within a few weeks of the onset of testosterone deficiency symptoms begin. Hypogonadism may increase the risk for type 2 diabetes, cardiovascular disease, premature death in older men, metabolic syndrome, and Alzheimer’s disease.

According to Boston University School of Medicine, approximately 4 to 5 million men in the United States, are affected with hypogonadism and low testosterone levels are commonly seen in older males. More than 60% of men over 65 years of age have free testosterone levels below the normal values of men between 30 to 35 years of age. A Study published in the Indian Journal of Endocrinology and Metabolism in the year 2017, estimates that prevalence of hypogonadism in type 2 diabetes patients was found to be 20.7%. Furthermore, the prevalence rate of hypogonadism in patients with type 2 diabetes was moderate with highest number of patients belonging to age group 50–59 year.

Increase in incidence and prevalence of hypogonadism, technological advancements in male hypogonadism therapy and rise in awareness about hypogonadism and its treatment option are the key driving factors in male hypogonadism market.

Scope of the Report

As per the scope of the report, Male hypogonadism or testosterone deficiency, is a failure of the testes to produce the male sex hormone testosterone, sperm, or both. It can be due to the result of a disease process involving the hypothalamus and pituitary gland or testicular disorder. Male hypogonadism market is segmented by therapy type, application and geography.

By Therapy Type
Testosterone Replacement Therapy
Gonadotropin-Releasing Hormones Therapy
Human Chorionic Gonadotropin (hCG)
Follicle-stimulating Hormone (FSH)
Gonadotropin-releasing Hormone (GnRH)
Other Gonadotropin Replacement Therapies
By Application
Kallmann Syndrome
Klinefelters Syndrome
Pituitary Disorders
Other Applications
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Gonadotropin-Releasing Hormones Therapy Segment is Expected to Hold a Major Market Share in the Male Hypogonadism Market

  • Gonadotropin releasing hormone stimulates to release follicle-stimulating hormone, and luteinizing hormone, which helps in regulating the gametogenic and steroidogenic functions of the gonads in males.
  • As per European Association of Urology 2016 report, incidence of hypogonadism in middle-aged men, varied from 2.1% to 12.8%, men aged 40-79 varied form 2.1% to 5.7%, in Europe. In addition, hypogonadism is more prevalent in older men with obesity and in men with a poor health status.
  • Gonadotropin-releasing hormones therapy segment holds a significant market share in male hypogonadism market and is anticipated to show similar trend over the forecast period. Moreover, due to rise in adoption of this therapy with increasing cases of hypogonadism in men are the key driving factors in the Gonadotropin-releasing hormones therapy segment.
Male Hypogonadism Market Forecast

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global male hypogonadism market due to increasing incidence and prevalence of hypogonadism and rise in awareness about hypogonadism and its treatment option in this region. According to the study published in European Association of Urology Journal in the year 2017, testosterone prescription trends in the United States estimated an increase between 1.8 and 4-fold over the last two decades (1997 - 2017). Furthermore, increasing research and development coupled with technologically advanced products and presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Male Hypogonadism Market Analysis

Competitive Landscape

The Male Hypogonadism Market is fragmented competitive and consists of a several major players. Some of the players in the market focus on technologically and innovation of advanced products to meet the growing demand of the product. Some of the companies which are currently dominating the market are Endo International Plc, AbbVie Inc, Pfizer Inc, Allergan Plc, Teva Pharmaceutical Industries Ltd, Eli Lilly and Company, Bayer AG, Merck & Co., Inc, Sun Pharmaceutical Industries Limited and Ferring Holding S.A.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Cases of Male Hypogonadism Worldwide

      2. 4.2.2 Technological Advancements in Male Hypogonadism Therapy

      3. 4.2.3 Growing Awareness Among Individuals Regarding Hypogonadism Treatment

    3. 4.3 Market Restraints

      1. 4.3.1 High Side Effects Associated with Treatment

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Therapy Type

      1. 5.1.1 Testosterone Replacement Therapy

      2. 5.1.2 Gonadotropin-Releasing Hormones Therapy

        1. 5.1.2.1 Human Chorionic Gonadotropin (hCG)

        2. 5.1.2.2 Follicle-stimulating Hormone (FSH)

        3. 5.1.2.3 Gonadotropin-releasing Hormone (GnRH)

        4. 5.1.2.4 Other Gonadotropin Replacement Therapies

    2. 5.2 By Application

      1. 5.2.1 Kallmann Syndrome

      2. 5.2.2 Klinefelters Syndrome

      3. 5.2.3 Pituitary Disorders

      4. 5.2.4 Other Applications

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Endo International Plc

      2. 6.1.2 AbbVie Inc

      3. 6.1.3 Pfizer Inc

      4. 6.1.4 Allergan Plc

      5. 6.1.5 Teva Pharmaceutical Industries Ltd

      6. 6.1.6 Eli Lilly and Company

      7. 6.1.7 Bayer AG

      8. 6.1.8 Merck & Co., Inc

      9. 6.1.9 Sun Pharmaceutical Industries Limited

      10. 6.1.10 Ferring Holding S.A

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Male Hypogonadism Market market is studied from 2018 - 2026.

The Male Hypogonadism Market is growing at a CAGR of 5.1% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Endo International Plc, AbbVie Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Allergan Plc are the major companies operating in Male Hypogonadism Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!